TL;DR
This study reveals significant racial differences in the genomic landscape of advanced prostate cancer (mCRPC), even when clinical outcomes appear similar. African American patients showed distinct tumor biology, with altered expression of key cancer pathways and different frequencies of specific gene fusions compared to European American patients, highlighting the need for diverse representation in cancer research.
What Problem Does This Paper Address?
Prostate cancer (PCa) disproportionately affects African American men, who experience higher incidence and mortality rates. While previous research has hinted at racial disparities in PCa genomics, most studies focused on localized disease. This paper tackles the critical gap in understanding how race influences the genomic characteristics of metastatic castration-resistant prostate cancer (mCRPC), the most aggressive and lethal form of the disease. The authors aim to investigate transcriptomic, mutational, and clinical differences by race in a large, multi-institutional cohort of mCRPC patients, moving beyond targeted gene panels to a more comprehensive genomic view.
Methods
The researchers aggregated genomic and clinicopathologic data from four mCRPC tumor biopsy cohorts. Key methods included:
- Whole-transcriptome RNA sequencing (RNA-seq): Used to analyze gene expression patterns.
- DNA sequencing (whole-genome and exome): Employed to identify DNA alterations like mutations, copy number variations, and structural variants.
- Gene Set Enrichment Analysis (GSEA): A standard bioinformatics technique used to assess pathway-level differences in gene expression between racial groups. Specifically, they used the Hallmark Pathways from MSigDb.
- Statistical Analysis: Wilcoxon rank-sum tests were used for continuous variables, Fisher's exact tests for categorical variables, and Kaplan-Meier methods with Cox proportional hazards for survival analysis.
- Batch Correction: An empirical Bayes framework was applied to standardize gene expression data across different cohorts.
Datasets
The study utilized aggregated data from four mCRPC cohorts:
- Fred Hutchinson Cancer Center (FHCC; N=63)
- Weill Cornell Medicine (WCM; N=27)
- Stand Up 2 Cancer / Prostate Cancer Foundation East Coast Dream Team (SU2C/PCF ECDT; N=255)
- West Coast Dream Team (WCDT; N=136)
A total of 445 patients with self-reported race and available genomic data were included in the final analysis. The study did not introduce a new benchmark dataset but rather combined existing ones to create a larger, more robust cohort for analysis.
Key Insights and Ideas
- Distinct Tumor Biology Despite Similar Outcomes: The most striking insight is that African American patients with mCRPC exhibit a measurably different tumor biology compared to European American patients, even though their overall survival and response to androgen receptor pathway inhibitor (ARPI) treatment were not statistically different in this cohort. This suggests that underlying genomic differences may not always translate to immediate clinical outcome disparities but could influence treatment response or disease progression in ways not captured by current metrics.
- MYC Pathway Overexpression in African Americans: Tumors from African American patients showed significantly higher expression of MYC pathway genes. The MYC oncogene is a well-known driver of cancer growth and proliferation, suggesting a potentially more aggressive intrinsic biology.
- Suppressed Immune and Inflammatory Pathways in African Americans: Conversely, African American patients displayed lower expression of IFN-γ, IL-6/JAK/STAT3, and general inflammatory pathway genes. These pathways are crucial for immune response and can influence tumor microenvironment and treatment sensitivity. The reduced expression of IFN-γ is particularly interesting, as recent studies suggest it can enhance sensitivity to taxane-based chemotherapy.
- TMPRSS2:ERG Fusion Disparities: The study confirmed previous findings of a significantly lower frequency of TMPRSS2:ERG gene fusions in African American patients compared to European American patients. This fusion is a common driver in PCa, and its differential prevalence by race is a key genomic distinction.
- Potential for Targeted Therapies: The observed racial differences in pathways like IFN-γ and JAK/STAT signaling have direct translational implications. Therapies targeting these pathways (e.g., JAK inhibitors) are emerging, and understanding racial variations in their activity could inform personalized treatment strategies.
Key Results
- Cohort Composition: Out of 481 profiled patients, 445 had race data. The cohort was predominantly European American (90%), with 6% Black/African American and 2% Asian.
- Pathway Expression Differences:
- African American patients showed higher expression of MYC pathway genes (FDR q=0.03).
- African American patients showed lower expression of IFN-γ (FDR q<0.001), IL-6/JAK/STAT3 (FDR q<0.001), and inflammatory pathway genes (FDR q<0.001) compared to European American patients.
- DNA Alteration Frequencies:
- TMPRSS2:ERG gene fusions were significantly more frequent in European American patients (41%) than African American patients (11%) (P=0.015).
- CDK12 alterations showed a trend towards higher rates in Asian (22%) and African American (13%) patients compared to European American (6%) patients (P=0.05).
- Clinical Outcomes: No significant differences in overall survival were observed across racial groups (P=0.9). PSA50 response to ARPI treatment was also not significantly different when stratifying by prior ARPI exposure.
Limitations and Future Work
- Small Sample Sizes for Non-European American Groups: The study acknowledges the limitation of small sample sizes for African American (N=26) and especially Asian (N=9) patients. This restricts the power to detect statistically significant differences for all observed trends, particularly for Asian patients where some alterations were nominally higher but not statistically significant. The authors emphasize the need for larger, more diverse cohorts, especially including Asian patients from Asia.
- Lack of Social Determinants of Health (SDOH) Data: The study could not interrogate factors like structural racism, income, or lifestyle, which may confound or contribute to observed racial differences in tumor biology. Future research should aim to integrate SDOH data.
- Need for Validation: The authors call for future studies to validate their findings, particularly regarding the lack of difference in clinical outcomes across racial groups and the observed genomic distinctions.
- Translational Research: The findings highlight the importance of diverse representation in future genomic profiling and translational research efforts. Understanding these racial differences is crucial for developing personalized cancer therapies and ensuring equitable outcomes. The potential clinical actionability of pathways like IFN-γ and JAK/STAT warrants further investigation in diverse patient populations.
Summary updated